Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).

After adjusted for those not having second line treatment, ICI treatment showed a trend to offer better OS, although the difference was not statically significant in multivariate analysis (HR 0.43; 95% CI 0.18–1.05; P = .065) (see Table S4, Supplemental Digital Content 6, which revealed the analysis of overall survival adjusted for patients not receiving second-line therapy). 4 Discussion We have presented the incidence and characteristics of lung cancer patients harboring KRAS mutations in Taiwan, where more than half of the lung cancer patients were never-smokers.

also in 53,322 other papers